RBC Capital Markets adjusted their outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $122.00 to $142.00. The firm maintained a Sector Perform rating on the stock. The upgrade comes as Morgan Stanley's stock trades near its 52-week high of $136.

Bank stocks have been on a post-election upswing, with the KBW Nasdaq Bank Index ( ^BKX) up 14% since Trump won the presidency. Morgan Stanley has notched a 17% gain. Investors have a dinner plate to choose from to explain the bullishness.

RBC Capital analyst Arun Viswanathan maintained a Buy rating on Ball (BALL – Research Report) yesterday and set a price target of $75.00. The

Morgan Stanley's profit more than doubled in the fourth quarter, fueled by a wave of dealmaking and stock sales that drove its revenue to a full-year record.

RBC Capital Markets analyst Maurice Choy identifies relative “safer havens” in the yield-heavy energy infrastructure sector, National Bank economist Warren Lovely noted the important fact that global interest in Canadian bonds remains high,

Citi (C), JPMorgan Chase (JPM), Goldman Sachs (GS), and Wells Fargo (WFC) report on Wednesday, while Bank of America (BAC) and Morgan Stanley (MS) release results on Thursday. RBC Capital markets ...

“We think Morgan Stanley benefits from favorable secular trends in the capital markets, wealth management, and investment banking,” he said in a research note. Morgan Stanley’s revenue from ...

In a report released today, James Edwardes Jones from RBC Capital maintained a Buy rating on Reckitt (RKT – Research Report), with a price

Brian McGill and Michael Hyser operate as Johns Creek Financial along with support-staff members Stacie Alexander and Alexis Griffin, according to the announcement. The team joined LPL's core platform, affiliating with the firm in a 1099 relationship and using a shared Form ADV.

RBC Capital analyst Gordon Ramsay CFA maintained a Hold rating on Ampol Limited (CTXAF – Research Report) on January 22 and set a price target

Morgan Stanley is exploring the possibility of offering crypto to clients and is currently discussing a “safe” way to expand its services with regulators.

Francois Cedric, the Chief Executive Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.86 billion market cap biotech company showing remarkable revenue growth of 162% over the last twelve months,